Difference between revisions of "Lipefilgrastim (Lonquex)"
Jump to navigation
Jump to search
m |
m |
||
Line 3: | Line 3: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
− | * | + | *2013-07-25: Initial authorization |
==Also known as== | ==Also known as== | ||
*'''Code name:''' XM22 | *'''Code name:''' XM22 |
Revision as of 00:59, 7 May 2023
Mechanism of action
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
History of changes in EMA indication
- 2013-07-25: Initial authorization
Also known as
- Code name: XM22
- Brand name: Lonquex